期刊文献+

荧光免疫层析法降钙素原检测试剂盒临床性能评估 被引量:7

Performance Evaluation of Fluorescence Immunochromatography Kit in Detection of Procalcitonin
在线阅读 下载PDF
导出
摘要 目的评估荧光免疫层析法试剂盒检测降钙素原的性能。方法参照美国临床实验室标准化协会(Clinical and Laboratory Standards Institute,CLSI)EP5-A和EP6-A文件方法,对荧光免疫层析法试剂盒(TEBSUN)检测降钙素原的精密度、线性、方法学比对、相对灵敏度和特异性进行评估。结果荧光免疫层析法试剂盒检测降钙素原精密度较好,低浓度和高浓度样本精密度的变异系数分别为8.3%和4.7%;线性验证试验结果显示,在试剂盒标示的检测范围内具有良好的线性梯度关系(r=0.9989);方法学比对结果显示,荧光免疫层析法试剂盒与梅里埃VIDAS酶联免疫荧光法分析系统的降钙素原试剂盒检测结果一致性良好(r=0.9770);在0.5和2.0 ng/ml两个浓度水平,荧光免疫层析法试剂盒相对于酶联免疫荧光法试剂盒的灵敏度和特异性均大于86%,与其测定结果的总体符合率为93.75%。结论荧光免疫层析法试剂盒检测降钙素原的精密度、线性、方法学比对、相对灵敏度和相对特异性等性能评价较好,适用于临床标本检测。 Objective To evaluate the performance of fluorescence immunochromatography kit in detec- ting procalcitonin. Methods According to the Clinical and Laboratory Standards Institute (CLSI) EP5-A and EP6-A, the performance of fluorescence immunoehromatography kit (TEBSUN) in detecting procalcitonin was evaluated in the aspects of precision, linearity, methodology comparison, relative sensitivity, and relative speci- ficity. Results The fluorescence immunochromatography kit showed high precision, the coefficients of variation (CV) of low and high concentration samples were 8.3% and 4.7% , respectively. Result of liner verification test showed good linear correlation within the indicated test range (r = 0. 9989). In methodology comparison tests, the fluorescence immunochromatography kit had good consistency with VIDAS enzyme-linked immunofluorescence kit ( r = 0. 9770 ). The relative sensitivity and specificity of the fluorescence immunochromatography kit compared with the enzyme-linked immunofluorescence kit were both higher than 86% at 0. 5 ng/ml and 2.0 ng/ml level. The total consistency of the two diagnostic kits was 93.75%. Conclusion The fluorescence immuno- chromatography kit has good performance in precision, linearity, methodology comparison, relative sensitivity, and relative specificity, suggesting that it meets the requirements of clinical tests.
出处 《协和医学杂志》 2016年第3期208-211,共4页 Medical Journal of Peking Union Medical College Hospital
关键词 降钙素原 荧光免疫层析法 酶联免疫荧光法 性能评估 procalcitonin fluorescence immunoehromatography enzyme-linked immunofluorescence performance evaluation
作者简介 通信作者:徐英春电话:010-69159766,E-mail:xycpumeh@139.com
  • 相关文献

参考文献7

  • 1Lee H. Procalcitonin as a biomarker of infectious diseases [J]. Korean J Intern Med, 2013, 28: 285-291.
  • 2Becker KL, Snider R, Nylon ES. Procalcitonin in sepsis and s'stemic inflammation: a harmful biomarker and a therapeutic target [J]. Br J Pharmacol, 2010, 159: 253-264.
  • 3降钙素原(PCT)急诊临床应用的专家共识[J].中华急诊医学杂志,2012,21(9):944-951. 被引量:683
  • 4CLS1. EP5-A. Evaluation of precision performance of clinical chemistry devices [S]. Wayne, PA: CLSI, 1999.
  • 5CLSI. EP6-A. Evaluation of the linearity of quantitative meas- urement procedures: a statistical approach [ S]. Wayne, PA: CLSI, 2003.
  • 6Morens DM, Fauci AS. Emerging Infectious Diseases: Threats to Human Health and Global Stability [ J ]. PLoS Pathog, 2013, 9: e1003467.
  • 7Schneider HG, Lain QT. Proealcitonin for the clinical labora- tory: a review [J]. Pathology, 2007, 39: 383-390.

二级参考文献121

  • 1Whang KT, Vath SD, Becker KL, et al. Procalcitonin and pro-inflammatory cytokine interactions in sepsis [ J]. Shock,2000,14(1): 73-78.
  • 2Nijsten MW, Olinga P, The TH,et al. Procalcitonin behaves as a fastresponding acute phase protein in vivo and in vitro [ J]. Crit Care Med, 2000, 28 (2): 458461.
  • 3Wiedermann FJ,Kaneider N,Egger P, et al. Migration of human monocytes in response to procalcitonin [J]. Crit Care Med, 2002 , 30(5): 1112-1117.
  • 4Hoffmann G, Totzke G, Seibel M, et al. In vitro modulation of inducible nitric oxide synthase gene expression and nitric oxide synthesis by procalcitonin [J]. Crit Care Med, 2001, 29 (1): 112-126.
  • 5Morgenthaler NG, Struck J, Chancerelle Y,et al. Production of procalcitonin (PCT) in non-thyroidal tissue after LPS injection [J]. Horm Metab Res, 2003 , 35 ( 5): 290-295.
  • 6Meisner M, Tschaikowsky K, Schnabel S, et al. Procalcitonin- influence of temperature,storage,anticoagulation and arterial or venous asservation of blood samples on procalcitonin concentrations [J]. EurJ Clin Chem Clin Biochem, 1997 , 35 ( 8): 597-601.
  • 7Huang DT, Weissfeld LA, Kellum JA, et al. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia [J]. Ann Emerg Med, 2008 , 52 (1): 48-58.
  • 8Kruger S, Ewig S, Marre R, et al. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes [J]. Eur Respir J,2008,31 (2): 349-355.
  • 9Hirakata Y,Yanagihara K, Kurihara S, et al. Comparison of usefulness of plasma procalcitonin and C-reactive protein measurements for estimation of severity in adults with community-acquired pneumonia [J]. Diagn Microbiol Infect Dis, 2008 , 61 (2): 170-174.
  • 10Chan YL, Tseng CP, Tsay PK, et al. Procalcitonin as a marker of bacterial infection in the emergency department : an observational study[J]. Crit Care, 2(XM, 8 (1): R12-20.

共引文献682

同被引文献55

引证文献7

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部